Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Immune recovery and immunologic remodeling after CD19-directed chimeric antigen receptor T cell therapy in autoimmune diseases

View Full Paper
Ask AI
Bookmark
Share

Authors

APAnn‐Christin PecherJSJan C. SchroederCFChristoph Faul

Discussion

Loading...

Member takes

Overview

Observational analysis shows immune recovery and stable vaccination titers in autoimmune diseases, suggesting effective immunologic remodeling post CART19 therapy.

Key Points

  • Immune recovery was effective, with stable immunoglobulin levels and manageable infectious risks following CART19 treatment in autoimmune diseases.
  • Systemic sclerosis, antisynthetase syndrome, and rheumatoid arthritis were common indications, with febrile neutropenia occurring in 44.4% early post-therapy.
  • Analysis of immune reconstitution revealed rapid recovery of T cell lineages and significant changes in regulatory T cells post CART19 treatment.
  • These findings suggest that immune remodeling post therapy may benefit patients with autoimmune diseases, with implications for future treatment approaches.

Cite This Study

Pecher et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e3f5https://doi.org/10.1182/blood-2025-2335
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Anti-CD19 chimeric antigen receptor T-cell therapy for patients with non-Hodgkin's lymphoma and concurrent autoimmune disease2025
  2. 2Real-world outcomes of autologous CD19-directed CAR T-cell therapy in relapsed/refractory large B-cell lymphoma: A single-center experience2025 · 1 citations
  3. 3Activity of autologous anti-CD19 chimeric antigen receptor T-cell therapy in CD19-negative large B-cell lymphoma: A cell therapy consortium real world experience2025
  4. 4Large B-cell lymphoma following CD19-directed CART-cell therapy failure: Impact of CAR construct on disease features and outcomes of subsequent therapies2025
  5. 5Humanized CD19 chimeric antigen receptor (CAR) T-cell therapy for high-risk and post-CAR relapse of B-cell acute lymphoblastic leukemia2025 · 1 citations